CD8 T-cell Infiltration as a Predictor of Renal Cancer Progression After Surgery

Abstract

Kidney cancer patients with AJCC/TNM Stage III disease represent a significant challenge in selecting the care that should be received after surgery. According to 2019 NCCN guidelines, the decision is whether these patients should either receive sunitinib, enter a clinical trial, or be placed on surveillance. Potentially, this may represent overtreatment or oversurveillance for some patients who are cured, and undertreatment for others. Currently, there are not good indicators to guide which path patients should be follow, thus, appropriate biomarkers are needed to improve prognostication for patients with this stage of disease.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1166795

Entities

People

  • Haydn Kissick

Organizations

  • Emory University

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Acquisition
  • Biological Markers
  • Biological Staining And Labeling
  • Biomedical Research
  • Cells
  • Data Analysis
  • Diseases And Disorders
  • Electronic Mail
  • Fibroblasts
  • Health Services
  • Image Processing
  • Kidney Cancer
  • Law
  • Lymphocytes
  • Maryland
  • Medical Personnel
  • Procurement
  • Professional Development
  • Students
  • Technology Transfer
  • Universities
  • Wisconsin

Fields of Study

  • Medicine

Readers

  • Oncology
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.